Hypokalemia News and Research

RSS
ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

ProStrakan acquires US commercial rights to Fareston for treatment of metastatic breast cancer

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Janssen receives FDA Priority Review for ZYTIGA sNDA to treat mCRPC

Eplerenone shown to reduce cumulative heart failure hospitalisations

Eplerenone shown to reduce cumulative heart failure hospitalisations

Pendrin a possible new target for diuretic therapy

Pendrin a possible new target for diuretic therapy

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Takeda launches EDARBYCLOR in the U.S. for treatment of hypertension

Two new studies focus on causes of arrhythmia and SCD

Two new studies focus on causes of arrhythmia and SCD

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

Takeda receives FDA approval for EDARBYCLOR to treat hypertension

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

FDA approves modernized labeling for ViroPharma's Vancocin Capsules

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Celgene reports final results from REVLIMID plus VIDAZA phase II study on higher-risk MDS

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Takeda receives FDA approval for VELCADE sNDA to treat MM

Takeda receives FDA approval for VELCADE sNDA to treat MM

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

Boehringer Ingelheim receives FDA approval for COMBIVENT RESPIMAT to treat COPD

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

New clinical data on Bristol-Myers Squibb's NULOJIX to be presented at ESOT 2011 congress

Antidepressant alert – Citalopram associated to heart rhythm disturbances

Antidepressant alert – Citalopram associated to heart rhythm disturbances

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

Health Canada approves Tasigna for newly diagnosed Philadelphia chromosome-positive CML

FDA approves NULOJIX

FDA approves NULOJIX

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Alnylam's ALN-VSP Phase I trial data on liver cancer presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011

Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011